CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2
Launched by COLUMBIA UNIVERSITY · Jul 19, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The CU-COMMITS trial is studying the long-term health effects of COVID-19 in Black and Latino communities in New York, specifically those who were diagnosed at Columbia University Irving Medical Center. The goal is to understand how COVID-19 has impacted these individuals and their households over time. Researchers will invite people who tested positive for COVID-19 to complete a survey about their current health and symptoms, review their medical history regarding COVID-19, and for some participants, to provide a nasal swab and blood sample to check for the virus and antibodies up to 12 months after their diagnosis.
To be eligible, participants must be at least 18 years old, have a medical record at New York-Presbyterian Hospital, and either have a confirmed COVID-19 diagnosis or have been hospitalized for COVID-19 after March 1, 2020. Those who choose to participate can expect to share their experiences and health updates through surveys, and some may undergo additional testing. This study is particularly important because it seeks to gather valuable information on how COVID-19 affects different individuals and their families, helping to improve care for these communities in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria - Objective 1 Participants:
- • 1. age 18 years and older
- • 2. having an electronic medical record at NYP
- • 3. laboratory confirmed COVID-19 infection diagnosed at NYP/CUIMC after March 1, 2020 or were diagnosed at least 9 months prior to administration of the online questionnaire on long-term outcomes and sequelae.
- • 4. Able to provide informed consent
- • Exclusion Criteria -
- • 1. Index cases less than 18 years of age.
- • 2. Not COVID-19 diagnosed
- Inclusion Criteria - Objective 2 Participants:
- • 1. age 18 years and older
- • 2. having an electronic medical record at NYP
- • 3. Hospitalized at NYP/CUIMC after March 1 2020, or at least 9 months prior to administration of the online questionnaire on long-term outcomes and sequelae
- • 4. Randomly selected: every 10th index case who was not hospitalized
- • 5. Able to provide informed consent AND
- • 6. Are willing to provide a nasal swab, blood sample in addition to completing the questionnaire.
About Columbia University
Columbia University, a prestigious Ivy League institution located in New York City, is a leading sponsor of clinical trials dedicated to advancing medical research and improving patient care. With a robust network of research facilities and a commitment to innovation, Columbia University collaborates with a diverse range of healthcare professionals and researchers to explore groundbreaking therapies and treatment methodologies. The university's clinical trials encompass various fields, including oncology, neurology, and public health, aiming to translate scientific discoveries into effective clinical applications. Columbia University is dedicated to maintaining the highest ethical standards and regulatory compliance, ensuring the safety and well-being of trial participants while contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Magdalena Sobieszczyk, MD, MPH
Principal Investigator
Columbia University
Delivette Castor, PhD
Principal Investigator
Columbia University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials